Manhattan Scientifics, Inc. Logo

Manhattan Scientifics, Inc.

MHTX

(1.8)
Stock Price

0,00 USD

-407.87% ROA

80.46% ROE

-1.27x PER

Market Cap.

2.237.124,00 USD

-2.3% DER

0% Yield

3524% NPM

Manhattan Scientifics, Inc. Stock Analysis

Manhattan Scientifics, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Manhattan Scientifics, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (78.73%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 PBV

The stock's low PBV ratio (-0.95x) suggests it's undervalued, making it an attractive opportunity for investors.

3 DER

The stock has a low debt to equity ratio (-3%), which means it has a small amount of debt compared to the ownership it holds

4 Graham Number

Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.

5 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

6 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

8 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

9 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

10 ROA

The stock's ROA (-257.82%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

11 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

Manhattan Scientifics, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Manhattan Scientifics, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Manhattan Scientifics, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Manhattan Scientifics, Inc. Revenue
Year Revenue Growth
1999 0
2000 250.000 100%
2001 0 0%
2002 156.000 100%
2003 300.000 48%
2004 150.000 -100%
2005 0 0%
2006 0 0%
2007 0 0%
2008 856.000 100%
2009 633.000 -35.23%
2010 1.686.000 62.46%
2011 687.000 -145.41%
2012 693.000 0.87%
2013 652.000 -6.29%
2014 642.000 -1.56%
2015 64.000 -903.13%
2016 150.000 57.33%
2017 142.000 -5.63%
2018 0 0%
2019 97.000 100%
2020 50.000 -94%
2021 50.000 0%
2022 50.000 0%
2023 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Manhattan Scientifics, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1999 960.000
2000 3.093.000 68.96%
2001 1.964.000 -57.48%
2002 865.000 -127.05%
2003 286.000 -202.45%
2004 125.000 -128.8%
2005 227.000 44.93%
2006 221.000 -2.71%
2007 210.000 -5.24%
2008 198.000 -6.06%
2009 25.000 -692%
2010 28.000 10.71%
2011 204.000 86.27%
2012 274.000 25.55%
2013 960.000 71.46%
2014 1.861.000 48.41%
2015 2.937.000 36.64%
2016 3.335.000 11.93%
2017 175.000 -1805.71%
2018 52.000 -236.54%
2019 8.000 -550%
2020 11.000 27.27%
2021 10.000 -10%
2022 11.000 9.09%
2023 12.000 8.33%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Manhattan Scientifics, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1999 0
2000 0 0%
2001 4.468.000 100%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 1.717.000 100%
2007 3.233.000 46.89%
2008 1.952.000 -65.63%
2009 1.005.000 -94.23%
2010 1.520.000 33.88%
2011 2.541.000 40.18%
2012 2.069.000 -22.81%
2013 1.500.000 -37.93%
2014 2.256.000 33.51%
2015 3.378.000 33.21%
2016 3.198.000 -5.63%
2017 2.056.000 -55.54%
2018 1.389.000 -48.02%
2019 1.114.000 -24.69%
2020 714.000 -56.02%
2021 727.000 1.79%
2022 718.000 -1.25%
2023 708.000 -1.41%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Manhattan Scientifics, Inc. EBITDA
Year EBITDA Growth
1999 -9.254.000
2000 -4.491.000 -106.06%
2001 -9.095.000 50.62%
2002 -3.360.000 -170.68%
2003 -2.825.000 -18.94%
2004 -2.628.000 -7.5%
2005 -1.407.000 -86.78%
2006 -2.045.000 31.2%
2007 -3.703.000 44.77%
2008 -1.135.000 -226.26%
2009 -362.000 -213.54%
2010 40.000 1005%
2011 -2.049.000 101.95%
2012 -1.468.000 -39.58%
2013 -1.581.000 7.15%
2014 -3.273.000 51.7%
2015 -5.458.000 40.03%
2016 -5.388.000 -1.3%
2017 -1.420.000 -279.44%
2018 6.060.000 123.43%
2019 -1.023.000 692.38%
2020 -673.000 -52.01%
2021 -685.000 1.75%
2022 -676.000 -1.33%
2023 -720.000 6.11%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Manhattan Scientifics, Inc. Gross Profit
Year Gross Profit Growth
1999 0
2000 250.000 100%
2001 0 0%
2002 156.000 100%
2003 300.000 48%
2004 150.000 -100%
2005 0 0%
2006 0 0%
2007 0 0%
2008 856.000 100%
2009 633.000 -35.23%
2010 1.555.000 59.29%
2011 575.000 -170.43%
2012 693.000 17.03%
2013 652.000 -6.29%
2014 642.000 -1.56%
2015 64.000 -903.13%
2016 150.000 57.33%
2017 -47.000 419.15%
2018 -7.000 -571.43%
2019 97.000 107.22%
2020 50.000 -94%
2021 50.000 0%
2022 50.000 0%
2023 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Manhattan Scientifics, Inc. Net Profit
Year Net Profit Growth
1999 -9.800.000
2000 -4.736.000 -106.93%
2001 -6.662.000 28.91%
2002 -4.028.000 -65.39%
2003 -2.569.000 -56.79%
2004 -1.517.000 -69.35%
2005 -219.000 -592.69%
2006 -1.694.000 87.07%
2007 -3.014.000 43.8%
2008 -2.142.000 -40.71%
2009 -446.000 -380.27%
2010 -43.000 -937.21%
2011 -2.287.000 98.12%
2012 -2.090.000 -9.43%
2013 -1.928.000 -8.4%
2014 -3.805.000 49.33%
2015 8.012.000 147.49%
2016 -6.108.000 231.17%
2017 1.546.000 495.08%
2018 -8.334.000 118.55%
2019 -1.227.000 -579.22%
2020 4.314.000 128.44%
2021 -3.665.000 217.71%
2022 -4.760.000 23%
2023 -1.048.000 -354.2%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Manhattan Scientifics, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1999 0
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Manhattan Scientifics, Inc. Free Cashflow
Year Free Cashflow Growth
1999 -1.491.000
2000 -4.059.000 63.27%
2001 -2.376.000 -70.83%
2002 -934.000 -154.39%
2003 -251.000 -272.11%
2004 -454.000 44.71%
2005 -751.000 39.55%
2006 -331.000 -126.89%
2007 -537.000 38.36%
2008 -700.000 23.29%
2009 -406.000 -72.41%
2010 462.000 187.88%
2011 -1.198.000 138.56%
2012 -1.078.000 -11.13%
2013 -1.143.000 5.69%
2014 -2.571.000 55.54%
2015 3.160.000 181.36%
2016 -4.571.000 169.13%
2017 -799.000 -472.09%
2018 -682.000 -17.16%
2019 -316.000 -115.82%
2020 -392.000 19.39%
2021 -421.000 6.89%
2022 -349.000 -20.63%
2023 -37.000 -843.24%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Manhattan Scientifics, Inc. Operating Cashflow
Year Operating Cashflow Growth
1999 -1.491.000
2000 -3.994.000 62.67%
2001 -2.373.000 -68.31%
2002 -934.000 -154.07%
2003 -251.000 -272.11%
2004 -445.000 43.6%
2005 -751.000 40.75%
2006 -331.000 -126.89%
2007 -537.000 38.36%
2008 -700.000 23.29%
2009 -406.000 -72.41%
2010 462.000 187.88%
2011 -1.196.000 138.63%
2012 -1.078.000 -10.95%
2013 -964.000 -11.83%
2014 -2.535.000 61.97%
2015 3.415.000 174.23%
2016 -4.558.000 174.92%
2017 -791.000 -476.23%
2018 -682.000 -15.98%
2019 -316.000 -115.82%
2020 -388.000 18.56%
2021 -421.000 7.84%
2022 -349.000 -20.63%
2023 -37.000 -843.24%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Manhattan Scientifics, Inc. Capital Expenditure
Year Capital Expenditure Growth
1999 0
2000 65.000 100%
2001 3.000 -2066.67%
2002 0 0%
2003 0 0%
2004 9.000 100%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 2.000 100%
2012 0 0%
2013 179.000 100%
2014 36.000 -397.22%
2015 255.000 85.88%
2016 13.000 -1861.54%
2017 8.000 -62.5%
2018 0 0%
2019 0 0%
2020 4.000 100%
2021 0 0%
2022 0 0%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Manhattan Scientifics, Inc. Equity
Year Equity Growth
1999 3.222.000
2000 2.868.000 -12.34%
2001 1.512.000 -89.68%
2002 -633.000 338.86%
2003 -1.159.000 45.38%
2004 -1.796.000 35.47%
2005 -1.662.000 -8.06%
2006 -2.384.000 30.29%
2007 -1.073.000 -122.18%
2008 -842.000 -27.43%
2009 -848.000 0.71%
2010 71.000 1294.37%
2011 37.000 -91.89%
2012 -797.000 104.64%
2013 -2.238.000 64.39%
2014 -832.000 -168.99%
2015 8.594.000 109.68%
2016 2.723.000 -215.61%
2017 8.161.000 66.63%
2018 -150.000 5540.67%
2019 -1.005.000 85.07%
2020 4.674.000 121.5%
2021 1.035.000 -351.59%
2022 -1.695.000 161.06%
2023 -2.606.000 34.96%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Manhattan Scientifics, Inc. Assets
Year Assets Growth
1999 3.730.000
2000 3.684.000 -1.25%
2001 2.897.000 -27.17%
2002 1.646.000 -76%
2003 1.225.000 -34.37%
2004 1.303.000 5.99%
2005 1.170.000 -11.37%
2006 594.000 -96.97%
2007 722.000 17.73%
2008 1.019.000 29.15%
2009 890.000 -14.49%
2010 1.927.000 53.81%
2011 2.105.000 8.46%
2012 1.853.000 -13.6%
2013 1.861.000 0.43%
2014 3.633.000 48.78%
2015 12.869.000 71.77%
2016 7.635.000 -68.55%
2017 10.846.000 29.61%
2018 2.660.000 -307.74%
2019 2.225.000 -19.55%
2020 6.848.000 67.51%
2021 3.454.000 -98.26%
2022 1.031.000 -235.01%
2023 432.000 -138.66%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Manhattan Scientifics, Inc. Liabilities
Year Liabilities Growth
1999 508.000
2000 816.000 37.75%
2001 1.385.000 41.08%
2002 2.279.000 39.23%
2003 2.384.000 4.4%
2004 3.099.000 23.07%
2005 2.832.000 -9.43%
2006 2.978.000 4.9%
2007 1.795.000 -65.91%
2008 1.861.000 3.55%
2009 1.738.000 -7.08%
2010 1.856.000 6.36%
2011 2.068.000 10.25%
2012 2.650.000 21.96%
2013 4.099.000 35.35%
2014 4.465.000 8.2%
2015 4.275.000 -4.44%
2016 4.912.000 12.97%
2017 2.685.000 -82.94%
2018 2.810.000 4.45%
2019 3.230.000 13%
2020 2.174.000 -48.57%
2021 2.419.000 10.13%
2022 2.726.000 11.26%
2023 3.038.000 10.27%

Manhattan Scientifics, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
-0
Net Income per Share
-0
Price to Earning Ratio
-1.27x
Price To Sales Ratio
-44.74x
POCF Ratio
-8.51
PFCF Ratio
-8.51
Price to Book Ratio
-0.86
EV to Sales
-44.16
EV Over EBITDA
-3.05
EV to Operating CashFlow
-8.4
EV to FreeCashFlow
-8.4
Earnings Yield
-0.79
FreeCashFlow Yield
-0.12
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0.02
Graham NetNet
-0.01

Income Statement Metrics

Net Income per Share
-0
Income Quality
0.2
ROE
0.8
Return On Assets
-4.08
Return On Capital Employed
0.47
Net Income per EBT
1.35
EBT Per Ebit
1.8
Ebit per Revenue
14.52
Effective Tax Rate
-0.35

Margins

Sales, General, & Administrative to Revenue
-14.28
Research & Developement to Revenue
-0.24
Stock Based Compensation to Revenue
0
Gross Profit Margin
1.04
Operating Profit Margin
14.52
Pretax Profit Margin
26.14
Net Profit Margin
35.24

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0
Free CashFlow per Share
-0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
0.38
Return on Tangible Assets
-4.08
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,00
Tangible Book Value per Share
-0
Shareholders Equity per Share
-0
Interest Debt per Share
0
Debt to Equity
-0.02
Debt to Assets
0.14
Net Debt to EBITDA
0.04
Current Ratio
0.05
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
-0.02
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0.03

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Manhattan Scientifics, Inc. Dividends
Year Dividends Growth

Manhattan Scientifics, Inc. Profile

About Manhattan Scientifics, Inc.

Manhattan Scientifics, Inc., a technology incubator, engages in the development and commercialization of life-enhancing technologies in the United States. It develops technologies in the areas of nano-technologies and nano-medicine. The company was formerly known as Grand Enterprises, Inc. Manhattan Scientifics, Inc. was founded in 1992 and is based in New York, New York.

CEO
Mr. Emmanuel Tsoupanarias
Employee
1
Address
244 Fifth Avenue
New York, 10001

Manhattan Scientifics, Inc. Executives & BODs

Manhattan Scientifics, Inc. Executives & BODs
# Name Age
1 Mr. Leonard C. Friedman
Secretary
70
2 Mr. Robert Romeo Proulx
President of Imagion
70
3 Mr. Marvin Maslow
Founder & Chairman of the Board
70
4 Mr. Emmanuel Tsoupanarias
President, Chief Executive Officer & Director
70

Manhattan Scientifics, Inc. Competitors